AKRO
Price
$48.29
Change
-$2.17 (-4.30%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
4.04B
93 days until earnings call
IDYA
Price
$22.83
Change
-$0.27 (-1.17%)
Updated
Aug 11, 03:38 PM (EDT)
Capitalization
2.02B
92 days until earnings call
Interact to see
Advertisement

AKRO vs IDYA

Header iconAKRO vs IDYA Comparison
Open Charts AKRO vs IDYABanner chart's image
Akero Therapeutics
Price$48.29
Change-$2.17 (-4.30%)
Volume$9.88K
Capitalization4.04B
IDEAYA Biosciences
Price$22.83
Change-$0.27 (-1.17%)
Volume$100
Capitalization2.02B
AKRO vs IDYA Comparison Chart in %
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. IDYA commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (AKRO: $50.46 vs. IDYA: $23.10)
Brand notoriety: AKRO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 79% vs. IDYA: 82%
Market capitalization -- AKRO: $4.04B vs. IDYA: $2.02B
AKRO [@Biotechnology] is valued at $4.04B. IDYA’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • AKRO’s TA Score: 4 bullish, 6 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both AKRO and IDYA are a bad buy in the short-term.

Price Growth

AKRO (@Biotechnology) experienced а +4.32% price change this week, while IDYA (@Biotechnology) price change was -4.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 12, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($4.04B) has a higher market cap than IDYA($2.03B). AKRO YTD gains are higher at: 81.380 vs. IDYA (-10.117). AKRO has higher annual earnings (EBITDA): -264.59M vs. IDYA (-356.46M). IDYA (693M) and AKRO (686M) have equal amount of cash in the bank . IDYA has less debt than AKRO: IDYA (26M) vs AKRO (36.6M). IDYA has higher revenues than AKRO: IDYA (7M) vs AKRO (0).
AKROIDYAAKRO / IDYA
Capitalization4.04B2.03B199%
EBITDA-264.59M-356.46M74%
Gain YTD81.380-10.117-804%
P/E RatioN/AN/A-
Revenue07M-
Total Cash686M693M99%
Total Debt36.6M26M141%
FUNDAMENTALS RATINGS
AKRO vs IDYA: Fundamental Ratings
AKRO
IDYA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
63
Fair valued
PROFIT vs RISK RATING
1..100
7577
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
4252
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (42) in the null industry is in the same range as IDYA (63). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's Profit vs Risk Rating (75) in the null industry is in the same range as IDYA (77). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's SMR Rating (96) in the null industry is in the same range as IDYA (96). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's Price Growth Rating (42) in the null industry is in the same range as IDYA (52). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's P/E Growth Rating (100) in the null industry is in the same range as IDYA (100). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROIDYA
RSI
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 19 days ago
77%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCSTX27.320.21
+0.77%
ClearBridge Sustainability Leaders FI
FRCSX60.090.23
+0.38%
Franklin Small Cap Value R6
ARZMX16.250.05
+0.31%
AMG River Road Small Cap Value Z
FTVZX33.770.01
+0.03%
FullerThaler Behav Md-Cp Val R6
VEXAX149.15-0.33
-0.22%
Vanguard Extended Market Index Admiral

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.02%
ETNB - AKRO
60%
Loosely correlated
+1.55%
SLS - AKRO
44%
Loosely correlated
-1.25%
IDYA - AKRO
38%
Loosely correlated
+3.08%
VTYX - AKRO
38%
Loosely correlated
+19.07%
MDGL - AKRO
37%
Loosely correlated
+1.00%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.08%
IMNM - IDYA
61%
Loosely correlated
-1.82%
SYRE - IDYA
60%
Loosely correlated
N/A
CGON - IDYA
60%
Loosely correlated
+2.05%
NRIX - IDYA
60%
Loosely correlated
-2.28%
XENE - IDYA
58%
Loosely correlated
-0.59%
More